REG - Creo Medical Group - Director/PDMR Share Dealings

Creo MedicalAnnouncement

21/10/2024 10:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241021:nRSU9613Ia&default-theme=true

RNS Number : 9613I  Creo Medical Group PLC  21 October 2024

 

 

LEI: 213800H188ZDCWWXFA21

 

 

21 October 2024

 

Creo Medical Group plc

("Creo" or the "Company")

 

Director/PDMR Share Dealings

 

Further to the announcements made on 30 September 2024 and 18 October 2024,
and pursuant to the recent fundraising, the Company confirms that the
following directors of the Company have acquired New Ordinary Shares at the
Issue Price of 24 pence per Ordinary Share as follows:

 

 

 Director/PDMR Name  No. of New Ordinary Shares Acquired  Resultant Shareholding post transaction  % of voting rights post transaction
 Kevin Crofton       2,916,666                            3,566,666                                0.87%
 Richard Rees        208,333                              3,036,540                                0.74%

 

 

 

 Creo Medical Group plc                                   www.creomedical.com (http://www.creomedical.com/)
 Richard Craven, Company Secretary                        Via Walbrook PR

 Cavendish Capital Markets Limited

 (Nominated Adviser, Joint Bookrunner and Joint Broker)   +44 (0)20 7220 0500
 Stephen Keys / Camilla Hume / George Lawson (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Bookrunner and Joint Broker)       +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 William Baunton (ECM)

 Walbrook PR Ltd                                          Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Phillip Marriage                          Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Kevin Crofton
 2   Reason for the notification
 a)  Position/status                                              Non-Executive Chairman
 b)  Initial notification/Amendment                               Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Creo Medical Group plc
 b)  LEI                                                          213800H188ZDCWWXFA21
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each
     Identification code                                          GB00BZ1BLL44
 b)  Nature of the transaction                                    Purchase of Ordinary Shares
 c)  Price(s) and volumes(s)                                      Price(s)                     Volume(s)
     £0.24                                                                                     2,916,666
 d)  Aggregated information                                       N/A single transaction
     Aggregated volume                                            N/A single transaction
     Price                                                        N/A single transaction
 e)  Date of the transaction                                      21 October 2024
 f)  Place of the transaction                                     London Stock Exchange

 

 

 

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Richard Rees
 2   Reason for the notification
 a)  Position/status                                              Chief Financial Officer
 b)  Initial notification/Amendment                               Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Creo Medical Group plc
 b)  LEI                                                          213800H188ZDCWWXFA21
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each
     Identification code                                          GB00BZ1BLL44
 b)  Nature of the transaction                                    Purchase of Ordinary Shares
 c)  Price(s) and volumes(s)                                      Price(s)                     Volume(s)
     £0.24                                                                                     208,333
 d)  Aggregated information                                       N/A single transaction
     Aggregated volume                                            N/A single transaction
     Price                                                        N/A single transaction
 e)  Date of the transaction                                      21 October 2024
 f)  Place of the transaction                                     London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGCBDGUGDDGSB